Fezolinetant pharma-grade active pharmaceutical ingredient is supplied as a white to off-white crystalline powder with an anhydrous molecular weight of 436.48 g/mol, molecular formula C₂₄H₂₅FN₄O₃, and CAS registry number 1629229-37-3. The material is designated non-compendial; release testing is therefore aligned with ICH Q6A, ICH Q7, and ICH Q11 rather than a specific United States Pharmacopeia or European Pharmacopoeia monograph. The approved oral reference product contains fezolinetant 45 mg administered once daily for moderate-to-severe vasomotor symptoms associated with menopause. The molecule acts as a selective neurokinin 3 receptor antagonist on hypothalamic KNDy neurons, reducing neurokinin B-mediated thermoregulatory dysregulation without direct activation of estrogen receptors. Representative API grades include FZNT-01-G for wet or dry granulation, FZNT-02-D for direct compression, and FZNT-03-I for injectable formulation development. Each grade is manufactured under ICH Q7, with analytical control supported by ICH Q2(R1) validation and impurity management according to ICH Q3A, ICH Q3C, ICH Q3D, and ICH M7. The API is not intrinsically sterile, and the oral solid dosage forms are manufactured under current good manufacturing practice governed by 21 CFR Part 210 and 21 CFR Part 211 after the API has been qualified under the appropriate active pharmaceutical ingredient GMP framework.

Because no compendial monograph is published for fezolinetant, the release file should contain a impurity control strategy justified under ICH Q11 Section 3.2 and a quality risk management description aligned with ICH Q9. The solid-state form is controlled by X-ray powder diffractometry because the approved oral tablet is a crystalline material. The main analytical burden is therefore the demonstration of identity, crystalline phase consistency, related substances, residual solvents, elemental impurities, water content, and particle size distribution. The absence of a monograph does not remove the requirement for a stability-indicating high-performance liquid chromatography method; the method is validated for specificity, linearity, accuracy, and precision according to ICH Q2(R1). Nitrosamine risk assessment is performed in alignment with ICH M7 and regional health authority guidance, with absence of N-nitrosodimethylamine confirmed at a limit derived from the acceptable intake established in the relevant regulatory assessment.

Fezolinetant Identity and Solid-State Control Requirements

Identity confirmation for release includes infrared spectral matching against a qualified reference standard, X-ray powder diffractogram matching against the designated crystalline pattern, and chromatographic retention time consistency with the reference standard. Differential scanning calorimetry and thermogravimetric analysis are used to support solid-state characterization, while residual solvent analysis is performed by headspace gas chromatography. The release specification is established from manufacturing process validation and stability data under ICH Q1A(R2). The specification below is a representative release panel for oral-grade fezolinetant API; injectable-grade material may require additional bioburden and bacterial endotoxin controls.

The XRPD diffractogram should be evaluated for crystalline phase consistency because changes in polymorphic form can alter dissolution behavior in tablet and capsule formulations. If micronization is used, an amorphous content limit should be established and verified by a method that is validated for the expected amorphous fraction. Water content is not a surrogate for hydrate formation; a separate polymorph stability assessment under ICH Q1A(R2) conditions is required to establish the retest period. Residual solvent release depends on the synthetic route, and the solvent panel should include both process solvents and any solvents introduced during purification or recrystallization. Elemental impurity control follows the ICH Q3D risk assessment for the actual synthetic route, with particular attention to palladium or other transition metal catalysts if used in coupling steps.

Particle size distribution, bulk density, and flowability are adjusted for each dosage form. FZNT-01-G for granulation is lot-controlled to laser diffraction D90 ≤80 µm and D50 20–60 µm, with bulk density 0.30–0.55 g/mL and tapped density 0.40–0.70 g/mL. FZNT-02-D for direct compression is micronized to D90 ≤20 µm and is supplied with bulk density 0.20–0.40 g/mL, which typically requires flow-aid addition to prevent ratholing in a tablet press hopper. FZNT-03-I for injectable formulation development is milled under reduced bioburden controls and is not terminally sterilized as an API. For capsule and tablet manufacturing, the API is pre-blended with a diluent at 1:1 w/w geometric dilution before high-shear mixing to reduce segregation; blend uniformity is assessed by stratified sampling and USP <905> criteria. In wet granulation, purified water is added to a binary pre-blend of API, lactose monohydrate, and binder, with granulation endpoint controlled by impeller torque or power consumption on the high-shear mixer. Drying in a fluid-bed dryer should maintain product temperature below 40°C unless stability-indicating data support a higher temperature; inlet air temperature 50–60°C is a common starting point for granule drying. Granules are screened through 0.8–1.2 mm screens before lubrication and compression. Direct compression blends are compressed on a rotary tablet press at target hardness 60–120 N depending on tablet geometry, but hardness specifications must be derived from disintegration and dissolution data, not press convenience.

Fezolinetant-containing oral formulations require dissolution testing as a release method only after the discriminatory power of the dissolution procedure has been demonstrated. pH solubility dependence and the effect of sodium lauryl sulfate concentration in media should be investigated during method development. For a BCS-based solubility classification, published data for this specific configuration is limited; therefore the dissolution method cannot be assumed from chemical structure alone. The approved oral commercial product is a tablet, but capsule and granule dosage forms can be developed using the same API when blend uniformity and dissolution equivalence are demonstrated against the intended clinical reference.

How Does Fezolinetant Differ from Estrogen-Based and Serotonergic Alternatives?

Fezolinetant differs from menopause hormone therapy because it does not supply estradiol, conjugated equine estrogens, or a progestogen. Receptor profiling shows no direct estrogen receptor alpha or beta agonist activity, and the approved prescribing information does not list endometrial stimulation or estrogen-dependent malignancy as pharmacologic effects. The clinical target is the neurokinin 3 receptor on KNDy neurons in the arcuate nucleus, where neurokinin B signaling is reduced rather than estrogen-mediated feedback pathways being replaced. This distinction is operationally relevant in the API specification because estrogenic impurities are not part of the control strategy, whereas chiral purity and related substances from the synthetic route are of primary concern. Compared with low-dose paroxetine mesylate used for vasomotor symptoms, fezolinetant acts by a different receptor pathway and therefore has a different adverse effect boundary. The serotonergic side effect profile associated with selective serotonin transporter inhibition is not the primary monitoring concern; instead, hepatic transaminase elevations are the key safety signal. Baseline alanine aminotransferase, aspartate aminotransferase, and total bilirubin are obtained before treatment initiation, repeated at 3 months, 6 months, and 9 months after initiation, and followed periodically in patients with elevations. Co-administration with strong CYP1A2 inhibitors is contraindicated because fezolinetant clearance depends substantially on CYP1A2-mediated oxidation. This hepatic and CYP1A2 interaction profile differentiates fezolinetant from over-the-counter botanical vasomotor preparations, which are not characterized by the same receptor selectivity or the same regulatory evidence base.

The API-level difference is that fezolinetant is a single enantiomer with chiral control required by chiral HPLC or equivalent method. In contrast, estradiol hemihydrate or micronized estradiol is a naturally occurring steroid controlled by steroidal impurity profiles under compendial monographs where applicable. Low-dose paroxetine mesylate is a salt of a chiral base; paroxetine has compendial monographs and is controlled for related substances, residual solvents, and chiral identity. Fezolinetant therefore presents a more recent non-compendial control challenge: the manufacturer must generate and justify acceptance criteria rather than defaulting to a compendial test battery. This does not reduce the rigor; it increases the need for ICH Q11 development history, route-specific impurity mapping, and stability-qualified analytical procedures.

For injectable formulation development, FZNT-03-I is a micronized grade with reduced bioburden and bacterial endotoxin limit based on the intended maximum parenteral dose per USP <85>. The API is not intrinsically sterile; terminal sterilization or aseptic filtration of the formulated solution is required. Published data for injectable fezolinetant configurations are limited; the approved reference product is an oral tablet. Solubility in aqueous buffers should be determined empirically as a function of pH, tonicity modifier, and cyclodextrin content, because solubility in pure water cannot be assumed from the oral absorption profile. If a solution dosage form is developed, filter compatibility should be confirmed with 0.22 µm PVDF or PES membranes because some neutral hydrophobic drug substances adsorb to filter surfaces and reduce recoverable potency. Terminal autoclaving at 121°C should not be used without stability-indicating data for degradation products; if steam sterilization is required, the effect on related substances and chiral purity must be monitored. For lyophilized injectable presentations, the API should be dissolved and sterile-filtered before lyophilization, and the reconstituted solution should be protected from light if photodegradation is observed during forced degradation studies. The oral grades should be stored in tightly closed containers protected from moisture, with controlled room temperature storage at 20–25°C and excursions permitted to 15–30°C only when justified by stability data under the chosen container closure system. Pre-drying before formulation is required if water content exceeds the release limit or if the API is exposed to ambient relative humidity above 60% for prolonged transfer operations.